Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the Sanofi Clinical Study Identification Number or study title by entering text and clicking search.

 

43 found

Click the study title to find more information about the study.

SANOFI-EFC6193
A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen

Medicine: Cabazitaxel, Condition: Prostatic Neoplasm, Prostate Cancer, Phase: 3, Clinical Study ID: EFC6193, Sponsor: Sanofi.
SANOFI-EFC11785
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

Medicine: Cabazitaxel, Condition: Prostatic Neoplasm, Prostate Cancer, Phase: 3, Clinical Study ID: EFC11785, Sponsor: Sanofi.
SANOFI-EFC11784
Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy

Medicine: Cabazitaxel, Docetaxel, Condition: Prostatic Neoplasm, Prostate Cancer, Phase: 3, Clinical Study ID: EFC11784, Sponsor: Sanofi.
SANOFI-DOCET_L_00714
A Phase IIb, Randomized, Multicenter, Noncomparative Pilot Study of the Safety and Efficacy of Three Docetaxel-Based Chemotherapy Regimens plus Bevacizumab ± Trastuzumab for the Adjuvant Treatment of Patients with Node Positive and High-Risk Node-Negative Breast Cancer (DOCET_L_00714)

Medicine: Docetaxel, Condition: Breast Cancer, Phase: 2, Clinical Study ID: DOCET_L_00714 , Sponsor: Sanofi.
SANOFI-RP56976-V-327
A multicenter phase III randomized trial comparing Taxotere administered either weekly or every three weeks in combination with prednisone versus Mitoxantrone in combination with prednisone for metastatic hormone-refractory prostate cancer

Medicine: Docetaxel, Condition: Prostatic Neoplasm, Prostate Cancer, Phase: 3, Clinical Study ID: RP56976-V-327, Sponsor: Sanofi.
SANOFI-M5I02
Safety and Immunogenicity of DTap-IPV (Diphtheria (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age

Medicine: DTaP-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed and Inactivated Poliovirus Vaccine), Condition: Tetanus; Diphth
SANOFI-SYNV00704
A Multi-Centre, Parallel, Double-Blind, Blinded Evaluator, Randomised, Placebo-Controlled Evaluation of the Efficacy and Safety of a Single Dose of 6 mL of Synvisc in Patients with Symptomatic Osteoarthritis of the Knee

Medicine: Hylan G-F 20, Condition: Osteoarthritis, knee, Phase: 3, Clinical Study ID: SYNV00704, Sponsor: Sanofi
SANOFI-EFC11628
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period

Medicine: Insulin Glargin 300 U/ml, Condition: Diabetes Mellitus Type 2, Phase: 3, Clinical Study ID: EFC11628, Sponsor: Sanofi
SANOFI-EFC11629
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination with Oral Antihyperglycemic Drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period

Medicine: Insulin Glargin 300 U/ml, Condition: Diabetes Mellitus Type 2, Phase: 3, Clinical Study ID: EFC11629, Sponsor: Sanofi
SANOFI-PDY12777
A 16-week, randomized, open-label, controlled study comparing the efficacy and safety of a new formulation of insulin glargine versus Lantus in patients with type 1 diabetes mellitus

Medicine: Insulin Glargin 300 U/ml, Condition: Diabetes Mellitus Type 1, Phase: 2, Clinical Study ID: PDY12777, Sponsor: Sanofi
First Previous 1 2 3 4 5 Next Last